Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
- Wednesday, June 23, 2021, 7:11
- Environment
- Add a comment
SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist (“TP-2021,” formerly JT-09) ProNeura®-based implant in an established 5′-guanidinonaltrindole (5′-GNTI)…
About the Author
adminasapcorp has written 41552 stories on this site.